These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18550179)

  • 41. Bone marrow-derived mast cells accumulate in the central nervous system during inflammation but are dispensable for experimental autoimmune encephalomyelitis pathogenesis.
    Bennett JL; Blanchet MR; Zhao L; Zbytnuik L; Antignano F; Gold M; Kubes P; McNagny KM
    J Immunol; 2009 May; 182(9):5507-14. PubMed ID: 19380799
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner.
    Rafei M; Campeau PM; Aguilar-Mahecha A; Buchanan M; Williams P; Birman E; Yuan S; Young YK; Boivin MN; Forner K; Basik M; Galipeau J
    J Immunol; 2009 May; 182(10):5994-6002. PubMed ID: 19414750
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemokines and disease.
    Gerard C; Rollins BJ
    Nat Immunol; 2001 Feb; 2(2):108-15. PubMed ID: 11175802
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The acute and chronic phases of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE) are ameliorated by the peroxynitrite decomposition catalyst, 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinatoiron (III) chloride, (FeTPPS).
    Bolton C; Scott GS; Smith T; Flower RJ
    Eur J Pharmacol; 2008 Dec; 601(1-3):88-93. PubMed ID: 18977216
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Statistical analysis of data from studies on experimental autoimmune encephalomyelitis.
    Fleming KK; Bovaird JA; Mosier MC; Emerson MR; LeVine SM; Marquis JG
    J Neuroimmunol; 2005 Dec; 170(1-2):71-84. PubMed ID: 16198426
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genistein down-modulates pro-inflammatory cytokines and reverses clinical signs of experimental autoimmune encephalomyelitis.
    De Paula ML; Rodrigues DH; Teixeira HC; Barsante MM; Souza MA; Ferreira AP
    Int Immunopharmacol; 2008 Sep; 8(9):1291-7. PubMed ID: 18602076
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis.
    Vogt J; Paul F; Aktas O; Müller-Wielsch K; Dörr J; Dörr S; Bharathi BS; Glumm R; Schmitz C; Steinbusch H; Raine CS; Tsokos M; Nitsch R; Zipp F
    Ann Neurol; 2009 Sep; 66(3):310-22. PubMed ID: 19798635
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of glutamate transporters GLT-1 and GLAST in different regions of rat brain during the course of experimental autoimmune encephalomyelitis.
    Mitosek-Szewczyk K; Sulkowski G; Stelmasiak Z; Struzyńska L
    Neuroscience; 2008 Jul; 155(1):45-52. PubMed ID: 18572325
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute neuroinflammation in Lewis rats - a model for acute multiple sclerosis relapses.
    Schneider C; Schuetz G; Zollner TM
    J Neuroimmunol; 2009 Aug; 213(1-2):84-90. PubMed ID: 19560215
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.
    Dhaiban S; Al-Ani M; Elemam NM; Maghazachi AA
    J Inflamm Res; 2020; 13():619-633. PubMed ID: 33061527
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemokines and autoimmune thyroid diseases.
    Liu C; Papewalis C; Domberg J; Scherbaum WA; Schott M
    Horm Metab Res; 2008 Jun; 40(6):361-8. PubMed ID: 18418812
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lessons from gene modified mice.
    Lira S
    Forum (Genova); 1999; 9(4):286-98. PubMed ID: 10611406
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunoneutralization of chemokines for the prevention and treatment of central nervous system autoimmune disease.
    Karpus WJ; Fife BT; Kennedy KJ
    Methods; 2003 Apr; 29(4):362-8. PubMed ID: 12725803
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemokines in autoimmune disease.
    Godessart N; Kunkel SL
    Curr Opin Immunol; 2001 Dec; 13(6):670-5. PubMed ID: 11677088
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Suppression of experimental autoimmune encephalomyelitis with antibodies against adhesion molecules].
    Kawai K; Kobayashi Y; Miyasaka M; Yoshikai Y; Sobue G
    Rinsho Shinkeigaku; 1995 Dec; 35(12):1504. PubMed ID: 8752445
    [No Abstract]   [Full Text] [Related]  

  • 56. Broad-spectrum chemokine inhibitors (BSCIs) and their anti-inflammatory effects in vivo.
    Grainger DJ; Reckless J
    Biochem Pharmacol; 2003 Apr; 65(7):1027-34. PubMed ID: 12663038
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gene therapy in experimental autoimmune encephalomyelitis.
    Mathisen PM; Tuohy VK
    J Clin Immunol; 2000 Sep; 20(5):327-33. PubMed ID: 11051274
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improvement of preclinical animal models for autoimmune-mediated disorders via reverse translation of failed therapies.
    't Hart BA; Jagessar SA; Kap YS; Haanstra KG; Philippens IH; Serguera C; Langermans J; Vierboom M
    Drug Discov Today; 2014 Sep; 19(9):1394-401. PubMed ID: 24704460
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CCL5-Glutamate Cross-Talk in Astrocyte-Neuron Communication in Multiple Sclerosis.
    Pittaluga A
    Front Immunol; 2017; 8():1079. PubMed ID: 28928746
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chemokine blockade as a therapy for renal disease.
    Rovin BH
    Curr Opin Nephrol Hypertens; 2000 May; 9(3):225-32. PubMed ID: 10847322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.